Review article · 2022 · Open access

Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers

Sakulrat Mankhong, Sujin Kim, Seongju Lee, Hyo‐Bum Kwak, Dong‐Ho Park, Kyung‐Lim Joa, Ju‐Hee Kang

Biomedicines, 10(4), 850 · Published 5 April 2022 · DOI 10.3390/biomedicines10040850

Open PDFView at the publisherCite this paper

In brief

“Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers” is a 2022 review article by Sakulrat Mankhong and 6 co-authors, published in Biomedicines. OpenAlex counts 81 citations as of 19 November 2026, which puts it in the top 2% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Biomedicines.

Citations
81
Most cited in
2024 (21)
Field-weighted impact
1.49
References
133
Authors
7

Abstract

In the 115 years since the discovery of Alzheimer's disease (AD), our knowledge, diagnosis, and therapeutics have significantly improved. Biomarkers are the primary tools for clinical research, diagnostics, and therapeutic monitoring in clinical trials. They provide much insightful information, and while they are not clinically used routinely, they help us to understand the mechanisms of this disease. This review charts the journey of AD biomarker discovery and development from cerebrospinal fluid (CSF) amyloid-beta 1-42 (Aβ42), total tau (T-tau), and phosphorylated tau (p-tau) biomarkers and imaging technologies to the next generation of biomarkers. We also discuss advanced high-sensitivity assay platforms for CSF Aβ42, T-tau, p-tau, and blood analysis. The recently proposed Aβ deposition/tau biomarker/neurodegeneration or neuronal injury (ATN) scheme might facilitate the definition of the biological status underpinning AD and offer a common language among researchers across biochemical biomarkers and imaging. Moreover, we highlight blood-based biomarkers for AD that offer a scalable alternative to CSF biomarkers through cost-saving and reduced invasiveness, and may provide an understanding of disease initiation and development. We discuss different groups of blood-based biomarker candidates, their advantages and limitations, and paths forward, from identification and analysis to clinical validation. The development of valid blood-based biomarkers may facilitate the implementation of future AD therapeutics and diagnostics.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022). Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers. Biomedicines, 10(4), 850. https://doi.org/10.3390/biomedicines10040850

MLA 9

Mankhong, Sakulrat, et al. “Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers.” Biomedicines, vol. 10, no. 4, 2022, p. 850. https://doi.org/10.3390/biomedicines10040850.

Chicago

Mankhong, Sakulrat, Sujin Kim, Seongju Lee, Hyo‐Bum Kwak, Dong‐Ho Park, Kyung‐Lim Joa, and Ju‐Hee Kang. 2022. “Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers.” Biomedicines 10 (4): 850. https://doi.org/10.3390/biomedicines10040850.

Harvard

Mankhong, S. et al. (2022) ‘Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers’, Biomedicines, 10(4), p. 850. doi:10.3390/biomedicines10040850.

IEEE

S. Mankhong et al., “Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers,” Biomedicines, vol. 10, no. 4, p. 850, 2022, doi: 10.3390/biomedicines10040850.

BibTeX

@article{mankhong2022development,
  title     = {{Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers}},
  author    = {Mankhong, Sakulrat and Kim, Sujin and Lee, Seongju and Kwak, Hyo‐Bum and Park, Dong‐Ho and Joa, Kyung‐Lim and Kang, Ju‐Hee},
  journal   = {Biomedicines},
  year      = {2022},
  volume    = {10},
  number    = {4},
  pages     = {850},
  doi       = {10.3390/biomedicines10040850},
  url       = {https://doi.org/10.3390/biomedicines10040850}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202288
20231313
20242121
20251818
20262121

Its field-weighted citation impact is 1.49: it has been cited 1.49 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • biomarkers
  • cerebrospinal fluid biomarkers
  • blood-based biomarkers
  • amyloid-beta 42
  • total tau
  • phosphorylated tau
  • amyloid imaging

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Mankhong, S., Kim, S., Lee, S., Kwak, H., Park, D., Joa, K., & Kang, J. (2022). Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers. Biomedicines, 10(4), 850. https://doi.org/10.3390/biomedicines10040850

How many times has this paper been cited?

81 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Biomedicines: sign in and open the PDF from this page.

Who wrote this paper?

Sakulrat Mankhong, Sujin Kim, Seongju Lee, Hyo‐Bum Kwak, Dong‐Ho Park, Kyung‐Lim Joa, Ju‐Hee Kang.

What is the DOI of this paper?

10.3390/biomedicines10040850, permanently at https://doi.org/10.3390/biomedicines10040850. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.